Home The Active Ingredient Matrix Atractylodes macrocephala (Atractylenolide I)

Formulation Intelligence

Atractylodes macrocephala (Atractylenolide I)

Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Atractylodes macrocephala (Atractylenolide I).

Atractylenolide I is a bioactive sesquiterpene lactone that exerts potent anti-inflammatory and gastroprotective effects primarily through the modulation of the TLR4/NF-κB signaling pathway and inhibition of pro-inflammatory cytokines.

Verified Molecular Profiling (NIH PubChem)

PubChem CID

5320935

Molecular Weight

594.9 g/mol

XLogP3 (Lipophilicity)

8.1

IUPAC Name

4-[(13R)-2,13-dihydroxy-13-[(5R)-5-(1-hydroxytridecyl)oxolan-2-yl]-9-oxotridecyl]-2-methyl-2H-furan-5-one

Pharmacokinetic Synergies & Enhancers

Proven Synergy Pairings

  • Paeoniflorin for enhanced synergistic protection of the gastric mucosa against oxidative stress
  • Hesperidin for improved gastrointestinal motility and metabolic regulation via synergistic MAPK pathway modulation

Biological Formulation Enhancers

  • Piperine for increased intestinal permeability and inhibition of first-pass metabolic enzymes
  • Quercetin for potential P-glycoprotein inhibition to enhance the systemic bioavailability of sesquiterpene lactones

Delivery System Constraints & Modeling

Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Atractylodes macrocephala (Atractylenolide I) across standard consumer modalities.

💊 Standard Capsules

The high lipophilicity of Atractylenolide I necessitates the use of lipid-based carriers or micronization to prevent poor dissolution and erratic absorption in standard dry powder capsules.

🍬 Gummy & Pectin Formats

The hydrophobic nature of sesquiterpene lactones can lead to phase separation or recrystallization within the pectin matrix, potentially compromising the structural integrity and dosage uniformity of the gummy.

🔬 Thin-Film Oral Strips

The low aqueous solubility and required therapeutic payload of Atractylodes extracts present significant challenges in maintaining film flexibility and preventing crystallization within the thin-film polymer matrix.

For Brand Founders

Formulate with Atractylodes macrocephala (Atractylenolide I)

Ready to launch a product featuring Atractylodes macrocephala (Atractylenolide I)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.

Build Science-Backed Formulation

Efficacy Evidence

Maximize Atractylodes macrocephala (Atractylenolide I) Bioavailability

Need absolute proof that your Atractylodes macrocephala (Atractylenolide I) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.

Simulate Bioavailability

For R&D Labs & CDMOs

Atractylodes macrocephala (Atractylenolide I) Degradation Testing

Is your Atractylodes macrocephala (Atractylenolide I) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.

Model Active Degradation